| Literature DB >> 27512369 |
Martina Ardizzi1, Marianna Ambrosecchia1, Livia Buratta2, Francesca Ferri3, Maurizio Peciccia2, Simone Donnari4, Claudia Mazzeschi2, Vittorio Gallese5.
Abstract
The present study focuses on the multifaceted concept of self-disturbance in schizophrenia, adding knowledge about a not yet investigated aspect, which is the interoceptive accuracy. Starting from the assumption that interoceptive accuracy requires an intact sense of self, which otherwise was proved to be altered in schizophrenia, the aim of the present study was to explore interoceptive accuracy in a group of schizophrenia patients, compared to healthy controls. Furthermore, the possible association between interoceptive accuracy and patients' positive and negative symptomatology was assessed. To pursue these goals, a group of 23 schizophrenia patients and a group of 23 healthy controls performed a heartbeat perception task. Patients' symptomatology was assessed by means of the Positive and Negative Syndrome Scale (PANSS). Results demonstrated significantly lower interoceptive accuracy in schizophrenia patients compared to healthy controls. This difference was not accounted for participants' age, BMI, anxiety levels, and heart rate. Furthermore, patients' illness severity, attention and pharmacological treatment did not influence their interoceptive accuracy levels. Interestingly, a strong positive relation between interoceptive accuracy and positive symptoms severity, especially Grandiosity, was found. The present results demonstrate for the first time that interoceptive accuracy is altered in schizophrenia. Furthermore, they prove a specific association between interoceptive accuracy and positive symptomatology, suggesting that the symptom Grandiosity might be protective against an altered basic sense of self in patients characterized by higher sensibility to their inner bodily sensations.Entities:
Keywords: basic self; bodily self; grandiosity; interoception; interoceptive accuracy; positive symptoms; schizophrenia; selfhood
Year: 2016 PMID: 27512369 PMCID: PMC4961721 DOI: 10.3389/fnhum.2016.00379
Source DB: PubMed Journal: Front Hum Neurosci ISSN: 1662-5161 Impact factor: 3.169
Demographic information about Schizophrenia patients (SCZ) and healthy controls (HC).
| SCZ | HC | |
|---|---|---|
| n. | 23 | 23 |
| Age (mean ± | 33.78 ± 6.33 | 31.91 ± 9.18 |
| Male sex, ( | 17–73.91 | 20–86.96 |
| Right handedness, (n° – %) | 20–86.96 | 21–91.30 |
| Body Mass Index (BMI), Kg/m2 (mean ± | 24.31 ± 2.31 | 23.27 ± 2.54 |
| Heart Rate (HR), bpm (mean ± | 86.48 ± 16.21 | 76.72 ± 15.59 |
| Diagnosis | ||
| Schizophrenia paranoid subtype, (n° – %) | 20–86.95 | n.a. |
| Schizoaffective disorder, (n° – %) | 3–13 | n.a. |
| Illness duration, year (mean ± | 9.22 ± 3.61 | n.a. |
| Structured Clinical Interview for DSM-IV Axis II disorders (SCID-II) | ||
| Cluster A, (n° – %) | 2–8.69 | n.a. |
| Cluster B, (n° – %) | 2–8.69 | n.a. |
| Cluster C, (n° – %) | 2–8.69 | n.a. |
| Global Assessment of Functioning Scale (GAF) (mean ± | 46.70 ± 7.60 | n.a. |
| Symptom Checklist-90-Revised (SCL-90-R) total score (mean ± | n.a. | 49.44 ± 9.05 |
| Positive and Negative Syndrome Scale for Schizophrenia (PANSS) | ||
| | 22.17 ± 8.16 | n.a. |
| Prevalence of Positive symptoms (n° – %) | 10–43.48 | n.a. |
| Delusions (mean ± | 3.65 ± 1,70 | n.a. |
| Conceptual disorganization (mean ± | 2.78 ± 1.28 | n.a. |
| Hallucinatory behavior (mean ± | 2.74 ± 1.54 | n.a. |
| Excitement (mean ± | 3.00 ± 1.62 | n.a. |
| Grandiosity (mean ± | 3.09 ± 1.70 | n.a. |
| Suspiciousness/persecution (mean ± | 3.87 ± 1.58 | n.a. |
| Hostility (mean ± | 3.04 ± 1.64 | n.a. |
| | 25.74 ± 7.65 | n.a. |
| Prevalence of Negative symptoms (n° – %) | 13–56.52 | n.a. |
| | 53.39 ± 12.42 | n.a. |
| Composite Scale (mean ± | -3.57 ± 10.45 | n.a. |
| Total (mean ± | 101.30 ± 22.38 | n.a. |
| State Anxiety Inventory (STAI-I) (mean ± | 47.23 ± 14.95 | 34.43 ± 7.49 ∗ |
| Chlorpromazine Equivalent, mg/die (mean ± | 389.77 ± 762.35 | n.a. |
| Intelligent Quotient (mean ± | 101.83 ± 13.10 | n.a. |
| Atypical antipsychotic | ||
| Risperidone, (n° – %) | 3–13.04 | n.a. |
| Olanzapine, (n° – %) | 7–30.43 | n.a. |
| Quetiapine, (n° – %) | 1–4.34 | n.a. |
| Ziprasidone, (n° – %) | 1–4.34 | n.a. |
| Aripiprazole, (n° – %) | 4–17.39 | n.a. |
Pearsons’ correlation coefficients (r) and p values (two-tailed) calculated between SCZ participants’ interoceptive accuracy and each item of the PANSS Positive Scale.
| Interoceptive Accuracy | 0.437 | 0.378 | 0.238 | 0.410 | 0.531 | 0.095 | 0.384 | |
| 0.037 | 0.075 | 0.274 | 0.052 | 0.009∗ | 0.667 | 0.070 | ||
| N. | 23 | 23 | 23 | 23 | 23 | 23 | 23 | |